Introduction {#sec1-1}
============

Thyroid nodule is a common presentation and requires a structured diagnostic approach to ascertain the risk of malignancy and determine appropriate management. With a 5-10% lifetime risk of developing a palpable thyroid nodule, they can be detected by palpation in 10% of women and 2% of men ^[@ref1]^. However, with high resolution ultrasound they can be detected in a 19-68% of the randomly selected population ^[@ref2]^. The risk of thyroid malignancy in a nodule depends on various factors attributable to the patient's history as well as clinical, sonological and metabolic features of the nodule, and is roughly estimated to be 3-15% ^[@ref3],[@ref4]^. Their accuracy in predicting the presence of malignancy is debatable. The clinical significance rests mainly on the need to exclude thyroid cancer, especially in so called incidentalomas or non-palpable lesions. Most guidelines recommend evaluation of only nodules greater than 1 cm owing to the greater potential to be clinically significant cancers. Occasionally, there may be nodules smaller than 1 cm that require evaluation because of suspicious sonological features or metabolic activity, associated lymphadenopathy, history of head and neck irradiation, or family history of thyroid cancer ^[@ref4]^.

Though patients with multiple nodules have the same risk of malignancy as those with a single nodule ^[@ref5]^, one large study found that a solitary nodule had a higher likelihood of malignancy than did a non-solitary nodule although the risk of malignancy per patient was the same and independent of the number of nodules ^[@ref6]^. Furthermore, the nodular gland may be secreting hormones normally, subnormally or supranormally. At present, any suspicious nodule on sonography is subjected to guided fine needle aspiration cytology (FNAC), the result of which decides the need for surgery. In about 15 to 30% of patients, the aspirate can be indeterminate ^[@ref7]^, which is associated with more than a 20% risk of malignancy. Hence, it is reasonable to conclude that a significant number of patients with nodules need surgery to exclude malignancy with the antecedent risk of recurrent laryngeal injury and permanent hypoparathyroidism.

While there is exhaustive literature on clinical and sonological cancer predicting risk factors in a nodule, recent area of research has been on biomarkers such as serum thyroid stimulating hormone (TSH), thyroglobulin (Tg) and antithyroglobulin (anti-Tg) antibody. Thus, the present study was planned to evaluate the potential role of these biochemical factors as preoperative indicators of thyroid malignancy.

Materials and methods {#sec1-2}
=====================

A prospective study of all eligible, willing patients presenting with thyroid swelling from May 2015 to December 2016 was planned and institutional ethical committee approval was given for the protocol. To be eligible, patients were to be 18 to 70 years old and willing to participate in the study. Patients with recurrent disease, diffuse thyroid enlargement, clinical hypothyroidism, thyrotoxicosis, proven extrathyroidal disease, poorly differentiated cytology, lymphoma or metastasis from elsewhere were excluded.

All study subjects were evaluated clinically with detailed history, physical examination, neck sonography, thyroid profile consisting of serum TSH, triiodothyronine and thyroxine, Tg, anti-Tg antibody and fine needle aspiration cytology. The size of the nodule as measured using a 10 mHz high frequency ultrasonographic probe. Based on the FNAC report, a treatment plan was made. A decision of hemi- or total thyroidectomy was made primarily on the FNAC report and secondarily on the presenting clinical scenario. The nodules where the preoperative FNAC was inconclusive (either suspicious or indeterminate), the hemithyroidectomy specimen were sent for frozen section analysis. Data on age and sex of subjects, voice change, number and size of the nodule/largest nodule, FNAC, frozen section and final histopathology findings along with the preoperative biomarker information such as serum levels of TSH, Tg and anti-Tg antibody were collected. Any further treatment and follow-up were done as per our standard practice.

Lesions were grouped as benign or malignant based on final histopathology, and based on this information, receiver operating characteristic curves (ROC) were plotted for serum Tg, Anti-Tg antibody and TSH levels.

Laboratory methods {#sec2-1}
------------------

Serum thyroglobulin, anti-thyroglobulin and thyroid stimulating hormone were determined using chemiluminescence immunoassay (CLIA), and processed using a Beckman Access-2 analyser (Beckman Coulter Access, GMI Inc, Germany).

Results {#sec1-3}
=======

During the study period, 110 patients presented with thyroid nodules, of which 18 were excluded. The majority of patients were women (72 of 92) and were 30 to 60 years old (51 of 92, [Tab. I](#table001){ref-type="table"}). On final histopathology, 47 patients harboured malignancy ([Tab. I](#table001){ref-type="table"}). The sensitivity, specificity, positive predictive value and negative predictive value for FNAC and frozen sections were 77%, 71%, 73%, 74% and 70%, 100%, 100% and 68%, respectively. The accuracy of FNAC was 71% and for frozen section was 73%.

Serum biomarkers {#sec2-2}
----------------

**Serum thyroglobulin (Tg)**: the levels of Tg varied from 0.1 to 500 ng/ml with a median of 29 ng/ml in patients with benign nodules compared to 0.3 to 816 ng/ml with a median of 162 ng/ml among malignant nodules ([Fig. 1](#fig001){ref-type="fig"}). A ROC curve was plotted as shown in [Figure 2](#fig002){ref-type="fig"}. Using ROC analysis, we obtained a cut-off of 53 ng/ml, with a sensitivity of 72%, specificity of 73% and a *p* value of \< 0.001 (Fishers exact test, [Fig. 2](#fig002){ref-type="fig"}, [Tab. II](#table002){ref-type="table"}).

**Serum anti-thyroglobulin (anti-Tg) antibody**: in the present study, mean serum anti-Tg antibody levels in benign and malignant nodules were 2.25 and 7.27 IU/ml, respectively, ([Fig. 3](#fig003){ref-type="fig"}) with median values of 1.1 and 0.9 IU/ml. On ROC analysis, there was no statistically significant association of anti-Tg antibody levels with risk of malignancy (P value = 0.34, Fischer exact test).

**Serum thyroid stimulating hormone (TSH)**: mean TSH in benign and malignant nodules were 1.94 and 2.15 mIU/L with a median of 1.6 mIU/L and 1.7 mIU/L, respectively ([Fig. 4](#fig004){ref-type="fig"}). On ROC analysis, there was no significant correlation with risk of malignancy (P value = 0.54, Fisher exact test).

Discussion {#sec1-4}
==========

Even if thyroid nodule is a common presentation, cancer is rare, representing 1% of all cancers. Accordingly, it requires a structured diagnostic approach to ascertain the risk of malignancy and determine appropriate management. Increasing incidence of thyroid nodules partly owing to incidental detection mandates us to improve our understanding on the risk factors and biomarkers that might help in guiding their management. While FNAC is a cost-effective, simple, outpatient procedure, its accuracy depends on the experience of the cytopathologist. The reported sensitivity and specificity of FNAC varies from 65 to 98% and 73-100% respectively ^[@ref7]^. The major reason for such a wide variation among studies are differences in categorisation of follicular neoplasms, suspicious of malignancy and atypical cell of unknown significance/follicular lesion of unknown significance. Common factors for false negatives are inadequate sampling due to calcified nodules, unguided FNAC, difference in inclusion of Bethesda categories under benign and malignant lesions and interobserver variability among reporting cytopathologists. While guided FNAC was not strictly mandated in our study, its sensitivity and specificity in diagnosing malignant nodules are comparable to other studies.

Currently, serum Tg is used in the follow-up of patients with well differentiated thyroid cancer (WDTC) to monitor disease recurrence. The diagnostic value of preoperative serum Tg is still an area of intense debate. Sands et al. in a retrospective study on 861 patients, of whom nearly 35% had indeterminate cytology, 81% with both indeterminate cytology and preoperative Tg ≥ 75 ng/ml had well-differentiated cancer on final pathology compared to 58% with indeterminate cytology alone (p = 0.014, RR = 1.4). They concluded that a combination of indeterminate cytology and preoperative Tg ≥ 75 ng/ml increased diagnostic efficacy compared to indeterminate cytology alone ^[@ref8]^. In another retrospective study of 164 patients with indeterminate cytology undergoing surgery, Lee et al. reported that a cut off Tg more than 70ng/ml predicted cancer risk in nodules more than 1.7 cm with a sensitivity and specificity of 67.7% and 60.7%, respectively. When the size of the nodule was ignored, a serum Tg value of more than 100 ng/ml predicted increased risk ^[@ref9]^. Another study of 97 follicular neoplasm by Lee et al. reported that preoperative serum Tg levels of 75 ng/ml or more and presence of calcification on ultrasonography predicted malignant risk ^[@ref10]^. Similarly, in our prospective study of 92 patients (of which 33 had indeterminate cytology), 76% of patients (13 of 17) with both indeterminate cytology and preoperative Tg \> 53 ng/ml had well differentiated cancer on final histopathology compared to 60% (20 of 33) of patients with indeterminate cytology alone. We also conclude that combination of indeterminate cytology and preoperative Tg \> 53 ng/ml increased diagnostic efficacy compared to indeterminate cytology alone. While indeterminate cytology was only 35% of our study population, a larger prospective study in this subset would answer whether serum Tg levels could predict risk of malignancy to guide surgery. Some authors have reported higher levels of preoperative serum Tg levels for diagnosing risk of malignancy ^[@ref11]^ .

It has been reported that the prevalence of WDTC is higher in patients with elevated anti-Tg antibody levels compared with the general population. The association between autoimmune thyroiditis and thyroid cancer is still not clear. A retrospective study of 1638 subjects by Kim et al. using multivariate regression analysis concluded that elevated anti-Tg antibody (odds ratio = 1.61; 95% CI: 1.21-2.23) and elevated serum TSH (odds ratio = 1.72; 95% CI: 1.12-2.63) were significantly associated with malignancy ^[@ref15]^. Another retrospective study of 854 patients by Vasileiadis et al. also concluded that tumour size \> 10 mm (*p* \< 0.001) and preoperative anti-Tg antibody levels (*p* = 0.003) were independent risk factors of malignancy ^[@ref16]^. A study on 108 patients reported that preoperative serum TSH level may be useful in predicting cancer in thyroid nodules. In that study, mean serum TSH in malignant vs benign nodules were 1.94 vs 1.16 mIU/L (*p* \< 0.005) ^[@ref17]^. Similarly, in a study of 63 patients, mean serum TSH in malignant and benign groups were 5.5 vs 1.4 mIU/L (*p* = 0.001) ^[@ref18]^. In the present study, we could not find no association of malignancy with either preoperative serum anti-Tg antibody or serum TSH levels in contrast with other studies ^[@ref19]^.

Conclusions {#sec1-5}
===========

Preoperative serum Tg may be a useful biomarker in differentiating benign from malignant thyroid nodules when a cut-off more than 53 ng/ml is used. Hence, we feel that preoperative Tg levels could be incorporated in counselling patients for surgery as well as the need for surgery. Its role in the background of indeterminate cytology needs further exploration through a large prospective study. We could not demonstrate any association between preoperative levels of serum anti-Tg or TSH with risk of malignancy.

Figures and tables {#sec1-6}
==================

![Distribution of serum Tg values in benign and malignant groups.](aoi-2020-01-33-g001){#fig001}

![ROC Curve of serum Tg values.](aoi-2020-01-33-g002){#fig002}

![Distribution of serum anti-Tg antibody levels in benign and malignant groups.](aoi-2020-01-33-g003){#fig003}

![Distribution of serum TSH among benign and malignant nodules.](aoi-2020-01-33-g004){#fig004}

###### 

Clinicopathological profile of the study subjects.

  Characteristic                Benign   Malignant   P value
  ----------------------------- -------- ----------- ---------
  **Age (years)**                                    
  45 or less                    23       23          0.83
  \> 45                         22       24          
  **Sex**                                            
  Female                        38       34          0.13
  Male                          07       13          
  **Size of nodule**                                 
  2 cm or less                  18       23          0.38
  \> 2 cm                       27       24          
  **Biomarkers (mean value)**                        
  TSH (IU/L)                    1.94     2.16        
  Tg (ng/ml)                    72.55    215.05      
  Anti-Tg antibody (IU/ml)      2.84     6.99        
  **FNAC**                                           
  Benign (n = 34)               27       07          
  Borderline (n = 9)            04       05          
  Suspicious (n = 24)           08       16          
  Malignant (n = 25)            05       20          
  **Frozen section**                                 
  Benign (n = 16)               11       05          
  Malignant (n = 12)            00       12          

###### 

Analysis of ROC curve and Chi-square test of Tg.

  ------------------------------ ----------
  Area under the curve           0.716
  ROC P value                    0.001
  Sensitivity                    72.3%
  Specificity                    73.3%
  Cut-off                        53 ng/ml
  p value (Fischer exact test)   \< 0.001
  ------------------------------ ----------
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